Anti-malarial Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Anti-malarial Drugs Market is segmented By Malaria Type (Plasmodium falciparum, Plasmodium malariae, Plasmodium vivax, Plasmodium ovale, Plasmodium knowlesi), By Drug Class (Aminoquinolines (Chloroquine, HydroxyChloroquine, Primaquine, Tafenoquine, Others), Quinoline-methanol (4-quinolinemethanols, Others), Cinchona Alkaloids (Quinine, Quinidine), Biguanides (Proguanil, Chlorproguanil), Sulfonamides (Sulfadoxine, Dapsone, Others), Sulfones, Artemisinin Derivatives, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Anti-malarial Drugs Market Overview

The Global "Anti-Malarial Drugs Market" is estimated to reach at a high CAGR during the forecast period (2022-2031).

Malaria is an infectious disease, which spreads through a bite of an infected female Anopheles mosquito, transferring parasites into the human body. Merozoites grow inside the red cells and destroy them, which further cause symptoms such as fever, tiredness, vomiting, and headache. The drugs that are used to treat and prevent malarial infections are called antimalarial.

Anti-malarial Drugs Market Dynamics

The market is predicted to grow due to increased research for novel medications and new combination therapies.

The different levels of the innovation system of antimalarial therapies in Nigeria and Burkina Faso are identified. The innovation systems approach explores the readiness of African countries for a transition to TACTs. The innovation systems approach assumes that integrating new technology in society is a collective effort in a complex social system. Triple artemisinin-based combination therapies (TACTs) are being developed to respond to artemisinin and partner drug resistance in the treatment of falciparum malaria in Southeast Asia. In African countries, where current artemisinin-based combination therapies (ACTs) are still effective, TACTs can benefit the larger community and future patients by mitigating the risk of drug resistance. This approach has become a well-established analytical tool in transition studies to generate insight into innovation barriers and define policy implications accordingly.

Side effects associated with anti-malaria drugs are expected to hamper market growth.

Most anti-malarial drugs are associated with severe side effects, which is expected to decrease demand for these drugs. For instance, Hydroxychloroquine main side effects are gastrointestinal upset (vomiting, diarrhea, stomach cramps), skin rash, headache, dizziness, and ocular toxicity. However, serious side effects, including arrhythmia, bronchospasm, angioedema, and seizures, rarely occur. Such factors are expected to hamper the market growth.

Industry Analysis

Porter’s Five Forces Analysis:

Supply Chain:

COVID-19 Impact on Anti-malarial Drugs Market

The COVID-19 pandemic has resulted in millions of infections, hundreds of thousands of deaths and major societal disruption due to lockdowns and other restrictions introduced to limit disease spread. Relatively little attention has been paid to understanding how the pandemic has affected malaria treatment, prevention, and control, which is a major cause of death and disease and predominantly affects people in less well-resourced settings. Malaria programs are being affected in many ways by COVID-19. To prevent malaria, insecticide-treated nets need regular renewal, but distribution campaigns have been delayed or cancelled. For detection and treatment of malaria, individuals may stop attending health facilities out of fear of exposure to COVID-19 or because they cannot afford transport. Health care workers require additional resources to protect themselves from COVID-19. Supplies of diagnostics and drugs are being interrupted, compounded by the production of substandard and falsified medicines and diagnostics. These disruptions are predicted to double the number of young African children dying of malaria in the coming year and may impact efforts to control the spread of drug resistance. However, the situation is expected to improve gradually in the forecast period.

Anti-malarial Drugs Market Segment Analysis

Artemisinin Derivatives segment is expected to hold the largest market share in the anti-malarial drugs market.

In 2020, the artemisinin derivatives segment accounted for the highest market share. Plasmodium falciparum parasites, the primary etiological agent of severe malaria, caused an estimated 229 million clinical cases and 409,000 deaths in 2019, predominantly in young African children. The disease is caused by the asexual blood stages, which complete their intra-erythrocytic developmental cycle (IDC) every 48 h. Globally, first-line treatment depends on artemisinin (ART)-based combination therapies (ACTs), which benefit from the exceptional potency of ART derivatives. The parasite activates these derivatives by hemoglobin-derived Fe2+-heme and kills rings and trophozoites via alkylation of proximal proteins, lipids, and heme. By combining two active ingredients with different mechanisms of action, ACTs are the most effective antimalarial medicines currently available in the market. For instance, the three standard ACTs (dihydroartemisinin-piperaquine, artesunate-mefloquine, and artemether-lumefantrine) and two TACTs containing partner drugs with opposing resistance mechanisms (dihydroartemisinin-piperaquine plus mefloquine and artemether-lumefantrine plus amodiaquine) for the treatment of malaria. However, the increasing consumption of artemisinin derivatives and monotherapies will boost the market in the forecast period.

Anti-malarial Drugs Market Geographical Share

The Middle East & Africa region holds the largest market share in the global anti-malarial drugs market

In 2020, the Middle East and Africa accounted for the highest revenue share. The region growth is attributed to the owing rapid surge in prevalence of malaria in the region. According to the World Health Organization, malaria is caused by five parasitic species, two of which – P. falciparum and P. vivax – are the most dangerous. The malaria parasite Plasmodium falciparum is the deadliest and most common on the African continent. In most places outside of Sub-Saharan Africa, P. vivax is the most common malaria parasite.

Moreover, the African region carries a disproportionately high share of the global malaria burden. In 2019, the region was home to 94% of all malaria cases and deaths. Nigeria (23 per cent), the Democratic Republic of the Congo (11 per cent), the United Republic of Tanzania (5 per cent), Burkina Faso (4 per cent), Mozambique (4 per cent), and Niger (4 per cent) accounted for over half of all malaria deaths globally (4 per cent). Therefore, the above statements it has increased the demand for anti-malarial drugs. Thus, the Middle East and Africa region has led to the highest market share in the forecast period.

Anti-malarial Drugs Market Competitive Landscape

Major key players in the anti-malarial drugs market are GlaxoSmithKline PLC, Cipla, Mylan N.V., F. Hoffmann-La Roche AG, Novartis AG, Ipca Laboratories Ltd. and Alvizia Health Care. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which contribute to the growth of the anti-malarial drugs market globally. For instance, On February 4, 2021, Zydus Cadila announced that its antimalarial compound ZY19489 (MMV253) is in development with Swiss-based product development partnership Medicines for Malaria Venture (MMV) has completed Phase I clinical evaluation [Reg’n Number ACTRN12619000127101]. In the first human study conducted in Australia, escalating doses of 25 to 1500 mg were administered to healthy human volunteers. A safety data review committee evaluated emerging pharmacokinetic (PK) and safety data.

Ipca Laboratories Limited:

Overview:

Ipca Laboratories Limited is an Indian multinational pharmaceutical company based in Mumbai, India. The company has been a crucial healthcare partner in over 120 countries across the 6 continents. It is a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Moreover, the company is one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva. It has leading brands in Pain, Rheumatology, Antimalarials and Haircare therapy. Additionally, four formulations rank amongst the top 300 brands of IPM as per IQVIA.

Product Portfolio: